{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AMR101",
    "query": {
      "intervention": "AMR101"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 25,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AMR101&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-10T12:14:03.852Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02781584",
      "title": "Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nonalcoholic Steatohepatitis (NASH)",
        "Nonalcoholic Fatty Liver Disease (NAFLD)"
      ],
      "interventions": [
        {
          "name": "SEL",
          "type": "DRUG"
        },
        {
          "name": "FIR",
          "type": "DRUG"
        },
        {
          "name": "CILO",
          "type": "DRUG"
        },
        {
          "name": "FENO",
          "type": "DRUG"
        },
        {
          "name": "VAS",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 220,
      "start_date": "2016-06-13",
      "completion_date": "2020-12-17",
      "has_results": true,
      "last_update_posted_date": "2022-03-16",
      "last_synced_at": "2026-09-10T12:14:03.852Z",
      "location_count": 12,
      "location_summary": "Chandler, Arizona • La Jolla, California • Los Angeles, California + 7 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02781584"
    },
    {
      "nct_id": "NCT06280976",
      "title": "Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Coronary Artery Disease",
        "Atherosclerosis",
        "Heart Attack"
      ],
      "interventions": [
        {
          "name": "Statin",
          "type": "DRUG"
        },
        {
          "name": "Aspirin tablet",
          "type": "DRUG"
        },
        {
          "name": "Nexlizet",
          "type": "DRUG"
        },
        {
          "name": "LEQVIO",
          "type": "DRUG"
        },
        {
          "name": "Vascepa",
          "type": "DRUG"
        },
        {
          "name": "Jardiance",
          "type": "DRUG"
        },
        {
          "name": "Colchicine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Louisville",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2024-03-01",
      "completion_date": "2025-01-01",
      "has_results": false,
      "last_update_posted_date": "2025-03-17",
      "last_synced_at": "2026-09-10T12:14:03.852Z",
      "location_count": 1,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06280976"
    },
    {
      "nct_id": "NCT00146211",
      "title": "TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Huntington Disease"
      ],
      "interventions": [
        {
          "name": "Ethyl-EPA (Miraxion™)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amarin Neuroscience Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "35 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2005-09",
      "completion_date": "2007-07",
      "has_results": false,
      "last_update_posted_date": "2007-12-27",
      "last_synced_at": "2026-09-10T12:14:03.852Z",
      "location_count": 35,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 31 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00146211"
    },
    {
      "nct_id": "NCT01047501",
      "title": "Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "AMR101 (ethyl icosapentate) - 4 g/day",
          "type": "DRUG"
        },
        {
          "name": "AMR101 (ethyl icosapentate) - 2 g/day",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amarin Pharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 702,
      "start_date": "2009-12",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2022-04-25",
      "last_synced_at": "2026-09-10T12:14:03.852Z",
      "location_count": 80,
      "location_summary": "Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more",
      "locations": [
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Scottsboro",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01047501"
    },
    {
      "nct_id": "NCT01369550",
      "title": "Efficacy Study of Stearidonic Acid (SDA) Soybean Oil-containing Foods on Red Blood Cell Fatty Acid Content",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy Volunteers",
        "Markers of Cardiovascular Risk"
      ],
      "interventions": [
        {
          "name": "SDA soybean oil-containing foods",
          "type": "OTHER"
        },
        {
          "name": "High-oleic sunflower oil containing foods",
          "type": "OTHER"
        },
        {
          "name": "Eicosapentaenoic acid",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Monsanto Company, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 127,
      "start_date": "2010-08",
      "completion_date": "2011-01",
      "has_results": false,
      "last_update_posted_date": "2011-06-09",
      "last_synced_at": "2026-09-10T12:14:03.852Z",
      "location_count": 2,
      "location_summary": "St. Petersburg, Florida • Addison, Illinois",
      "locations": [
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Addison",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01369550"
    },
    {
      "nct_id": "NCT02422446",
      "title": "Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes",
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Icosapent ethyl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "30 Years to 75 Years"
      },
      "enrollment_count": 2,
      "start_date": "2015-04",
      "completion_date": "2017-03-01",
      "has_results": true,
      "last_update_posted_date": "2022-03-18",
      "last_synced_at": "2026-09-10T12:14:03.852Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02422446"
    },
    {
      "nct_id": "NCT00001146",
      "title": "Omega-3 Fatty Acids in the Treatment of Bipolar Disorder: A Double-Blind, Placebo-Controlled Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bipolar Disorder",
        "Involutional Depression",
        "Mood Disorder"
      ],
      "interventions": [
        {
          "name": "Ethyl Eicosapentaenoic Acid",
          "type": "DRUG"
        },
        {
          "name": "OmegaBrite",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Mental Health (NIMH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 240,
      "start_date": "1999-10",
      "completion_date": "2002-08",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-09-10T12:14:03.852Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001146"
    },
    {
      "nct_id": "NCT01154985",
      "title": "Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "Placebo capsule",
          "type": "DRUG"
        },
        {
          "name": "EPA-E 300 mg capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mochida Pharmaceutical Company, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 243,
      "start_date": "2010-06",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2014-11-20",
      "last_synced_at": "2026-09-10T12:14:03.852Z",
      "location_count": 33,
      "location_summary": "Dothan, Alabama • Tucson, Arizona • Anaheim, California + 27 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01154985"
    },
    {
      "nct_id": "NCT02719327",
      "title": "Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "icosapent ethyl (IPE)",
          "type": "DRUG"
        },
        {
          "name": "gel cap placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "50 Years to 75 Years"
      },
      "enrollment_count": 131,
      "start_date": "2017-06-08",
      "completion_date": "2023-09-29",
      "has_results": true,
      "last_update_posted_date": "2024-11-26",
      "last_synced_at": "2026-09-10T12:14:03.852Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02719327"
    },
    {
      "nct_id": "NCT01047683",
      "title": "Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "AMR101 (ethyl icosapentate) - 4 g/day",
          "type": "DRUG"
        },
        {
          "name": "AMR101 (ethyl icosapentate) - 2 g/day",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amarin Pharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 229,
      "start_date": "2009-12",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2022-04-25",
      "last_synced_at": "2026-09-10T12:14:03.852Z",
      "location_count": 18,
      "location_summary": "Sacramento, California • Golden, Colorado • Miami, Florida + 13 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Golden",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01047683"
    }
  ]
}